Drug Database
Back to search

France· FR:69565055

LOJUXTA 20 mg, gélules

A lomitapide product containing mésilate de lomitapide, registered in France by CHIESI FARMACEUTICI, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC C10AX12

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedLOJUXTA 20 mg, gélulesATCC10AX12REGISTER NO.FR:69565055PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about mésilate de lomitapideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lomitapide is registered in 14 of 19 countries.

Countries holding a registration under ATC C10AX12 (lomitapide), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose
Search lomitapide products by name

Lomitapide · ATC C10AX12

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
MÉSILATE DE LOMITAPIDE
Manufacturer
CHIESI FARMACEUTICI
Country
France (FR)
ATC code
C10AX12
ATC class
Lomitapide
Defined daily dose
40 mg, O
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400927626135
    flacon(s) polyéthylène haute densité (PEHD) de 28 gélule(s)
    EUR 20.61

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

299 interactions on record for lomitapide.

Graded by severity as the source publishes them — 206 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lomitapide against other medicinesHow interaction checks work

Lomitapide · interactions on record

299 records

  • 206 severe
  • 86 moderate
  • 7 minor

Most severe, free to view

  • ClotrimazoleA01AB18severe
  • AprepitantA04AD12severe
  • Chenodeoxycholic acidA05AA01severe
  • SulfasalazineA07EC01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lomitapide in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lomitapide products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Lojuxta
  • Liechtenstein · Lojuxta
  • Norway · Lojuxta

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0212bd32-35d5-4258-9554-1a00cdbb369f
GET /v1/drugs/0212bd32-35d5-4258-9554-1a00cdbb369f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "69565055",
  "date_amm": "2013-07-31",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/13/851",
  "substance": "MÉSILATE DE LOMITAPIDE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "gélule",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}
API referenceMCP serverPlans

See everything about lomitapide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console